Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans

Annals of the New York Academy of Sciences

Volumn 1068, Issue 1, 2006, Pages 560-563

  Zaidi, Mone ^a   Epstein, Solomon ^a   Friend, Keith ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Bisphosphonates; Bone turnover markers; C telopeptides; Ibandronate; Kinetic pharmacodynamic modeling; Postmenopausal osteoporosis

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MODEL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 33744733983     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1346.058     Document Type: Conference Paper

References (11)

1. Rogers, M.J. 2003. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9 : 2643 2658.
2. Barrett, J., E. Worth, F. Bauss, et al. 2004. Ibandronate: a clinical pharmacological and pharmacokinetic update. J. Clin. Pharmacol. 44 : 951 965.
3. Pillai, G., R. Gieschke, T. Goggin, et al. 2004. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br. J. Clin. Pharmacol. 58 : 618 631.
4. Gieschke, R & N. Hayashi. 2002. Exploring oral and intravenous ibandronate dosing regimens by clinical trial simulation abstract P36 Osteoporos. Int. 13 Suppl 3 S23.
5. Gieschke, R. & J.-Y. Reginster. 2004. Successful prediction of biomarker response to oral monthly ibandronate abstract P359SU Osteoporos. Int. 15 Suppl 1 doi: 10.1007s00198-004-1620 S97.
6. Reginster, J.Y., K.M. Wilson, E. Dumont, et al. 2005. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J. Clin. Endocrinol. Metab. 90 : 5018 5024.
7. Miller, P.D., M.R. McClung, L. Macovei, et al. 2005. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone Miner. Res. 20 : 1315 1322.
8. Hochberg, M.C., S. Greenspan, R.D. Wasnich, et al. 2002. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metab. 87 : 1586 1592.
9. Garnero, P., O. Borel & P.D. Delmas. 2001. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin. Chem. 47 : 694 702.
10. Reginster, J.-Y., S. Adami, P. Lakatos, et al. 2006. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann. Rheum. Dis. Pub. 65 : 654 661.
11. Gorai, I., Y. Taguchi, O. Chaki, et al. 1998. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J. Clin. Endocrinol. Metab. 83 : 326 332.